AGA Principles of GI for the NP and PA virtual course and IBD Pharmacology Series Part II

AGA’s Principles of GI for the NP and PA is the medical industry’s premiere annual course for advanced practice providers (APPs). In response to the COVID-19 pandemic, AGA is partnering with Practicing Clinicians Exchange (PCE) to host the course virtually on August 15-16, 2020. The interactive format will allow audience engagement and knowledge checks as well as Q&A with faculty, attendee polling and note taking features. The course includes a broad overview of GI diseases including upper and lower GI disorders, IBD, IBS, NASH and NAFLD with a focus on the role of the APP in the GI care team.

The novel coronavirus pandemic has greatly impacted GI healthcare professionals and patient care. Emerging evidence shows over half of coronavirus patients may experience GI symptoms including diarrhea, nausea, vomiting and abdominal pain. Special considerations for the treatment of GI patients with COVID-19 including risks and complications will be included in the virtual course. Participants will be able to choose session tracks for early career and advanced career stages. These topics will include on-boarding to the GI practice, nutrition in GI, manometry interpretation and more.

For more information on sponsorships, please contact Amy Woodward, Senior Director, Corporate Relations.

AGA continues to expand its catalog of education for APPs. The first phase of the Advanced Practice Provider Pharmacology: IBD on-demand educational series, developed with independent educational grants from Gilead Sciences and Takeda Pharmaceuticals U.S.A., Inc., launched successfully in June 2019. The online course has drawn over 580 participants with over 200 continuing education certificates granted. Part II of this series: Use of Biologic and Oral Small-Molecule therapy for the pharmacological management of IBD, will launch in fall 2020. The second module will include an update on TNF antagonist (anti-TNF), Anti-Integrin, Interleukin, and Janus Kinase (JAK) inhibitor therapies for the pharmacological management of IBD. Faculty will discuss mechanisms of action, dosing, pharmacokinetics, side effects, and considerations for special populations.